Clinical trial • Phase I • Oncology
Tarlatamab for Small cell lung cancer | Small cell lung cancer (extensive stage)
Phase I trial of Tarlatamab for Small cell lung cancer | Small cell lung cancer (extensive stage). 274 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Small cell lung cancer | Small cell lung cancer (extensive stage)
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 06-06-2024
- First CTIS Authorization Date
- 18-07-2024
Trial design
Phase I trial across 9 sites in Netherlands, Austria, Spain and others.
- Target Sample Size
- 274
Recruitment
- Planned Sample Size
- 274
- Recruitment Window Months
- 119
Geography
- Total Number Of Sites
- 9
- Total Number Of Participants
- 118
Netherlands
- Latest Decision Or Authorization Date
- 27-01-2025
- Number Of Sites
- 1
- Number Of Participants
- 10
Sites
- Site Name
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Department Name
- Medical Oncology
- Principal Investigator Name
- Neeltje Steeghs
- Principal Investigator Email
- n.steeghs@nki.nl
- Contact Person Name
- Neeltje Steeghs
- Contact Person Email
- n.steeghs@nki.nl
Austria
- Latest Decision Or Authorization Date
- 21-01-2026
- Number Of Sites
- 1
- Number Of Participants
- 4
Sites
- Site Name
- Medical University Of Graz
- Department Name
- Division of Oncology
- Principal Investigator Name
- Philipp Jost
- Principal Investigator Email
- philipp.jost@medunigraz.at
- Contact Person Name
- Philipp Jost
- Contact Person Email
- philipp.jost@medunigraz.at
Spain
- Latest Decision Or Authorization Date
- 21-01-2026
- Number Of Sites
- 3
- Number Of Participants
- 65
Sites
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- Oncología Médica
- Principal Investigator Name
- Noemi Reguart Aransay
- Principal Investigator Email
- nreguart@clinic.cat
- Contact Person Name
- Noemi Reguart Aransay
- Contact Person Email
- nreguart@clinic.cat
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Oncología
- Principal Investigator Name
- Luis Paz-Ares Rodriguez
- Principal Investigator Email
- lpazaresr@seom.org
- Contact Person Name
- Luis Paz-Ares Rodriguez
- Contact Person Email
- lpazaresr@seom.org
- Site Name
- Hospital Universitario Ramon Y Cajal
- Department Name
- Oncología
- Principal Investigator Name
- Maria Eugenia Olmedo Garcia
- Principal Investigator Email
- maruolmedogarcia@hotmail.com
- Contact Person Name
- Maria Eugenia Olmedo Garcia
- Contact Person Email
- maruolmedogarcia@hotmail.com
Poland
- Latest Decision Or Authorization Date
- 26-01-2026
- Number Of Sites
- 2
- Number Of Participants
- 5
Sites
- Site Name
- Europejskie Centrum Zdrowia Otwock Sp. z o.o.
- Department Name
- Oncology
- Principal Investigator Name
- Cezary Szczylik
- Principal Investigator Email
- koordynator.badanklinicznych@ecz-otwock.pl
- Contact Person Name
- Cezary Szczylik
- Contact Person Email
- koordynator.badanklinicznych@ecz-otwock.pl
- Site Name
- Biokinetica S.A.
- Department Name
- Oncology
- Principal Investigator Name
- Rafał Stec
- Principal Investigator Email
- office@biokinetica.com
- Contact Person Name
- Rafał Stec
- Contact Person Email
- office@biokinetica.com
France
- Latest Decision Or Authorization Date
- 19-01-2026
- Number Of Sites
- 1
- Number Of Participants
- 23
Sites
- Site Name
- Institut Gustave Roussy
- Department Name
- Service des Innovations Therapeutiques et Essais precoces (DITEP)
- Principal Investigator Name
- Kaissa Ouali
- Principal Investigator Email
- kaissa.ouali@gustaveroussy.fr
- Contact Person Name
- Kaissa Ouali
- Contact Person Email
- kaissa.ouali@gustaveroussy.fr
Germany
- Latest Decision Or Authorization Date
- 22-01-2026
- Number Of Sites
- 1
- Number Of Participants
- 11
Sites
- Site Name
- Universitaetsklinikum Wuerzburg AöR
- Department Name
- Comprehensive Cancer Center Mainfranken (CCCM)
- Principal Investigator Name
- Horst-Dieter Hummel
- Principal Investigator Email
- hummel_h@ukw.de
- Contact Person Name
- Horst-Dieter Hummel
- Contact Person Email
- hummel_h@ukw.de
Sponsor
Primary sponsor
- Full Name
- Amgen Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- Tarlatamab
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)